Skip to content

A self-controlled trial treating patients with knee osteoarthritis using a nano-enabled Lidocaine delivery acupuncture needle(Lidocaine nd-Acu)

A self-controlled trial project treating patients with knee osteoarthritis using a nano-enabled Lidocaine delivery acupuncture needle(Lidocaine nd-Acu)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000169
Enrollment
Unknown
Registered
2024-08-05
Start date
2026-03-23
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis

Interventions

treating group ( 1 group):a nano-enabled Lidocaine delivery acupuncture needle(Lidocaine nd-Acu)

Sponsors

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) age from 45 to 80 years old; 2)patients meet the diagnostic criteria for knee osteoarthritis according to the 2014 National Institute for Health and Clinical Excellence criteria of the United Kingdom; 3) In recent 6 months, Kellgren and Lawrecne's radiological diagnostic criteria were in line with Grade I to Grade III; 4) The average severity of knee pain in the past week was more than 4 points (0 points representing no pain, 10 points representing extreme pain, a total of 11 scales); 5) male or female; 6) patients who signed informed consent and volunteer to participate in this project.

Exclusion criteria

Exclusion criteria: patients with a history of knee replacement surgery; 2) knee pain caused by other diseases (e.g. joint loosening, infection, malignancy, autoimmune disease, trauma, etc.). Patients with acute and chronic periarticular synovitis, bursitis, ligamentitis and other soft tissue inflammation should be evaluated by doctors to decide whether to enter the group; 3) had undergone arthroscopy or intra-articular injection within 1 year; 4) pregnant or lactating women; 5) severe acute/chronic organic or mental illness; 6) coagulation disorders (such as hemophilia); 7) participated in other clinical studies in the past three months.

Design outcomes

Primary

MeasureTime frame
Western Ontario and McMaster Universities Osteoarthritis index,WOMAC score;Venous blood plasma inflammatory factor IL-1/IL-6/TNF-a;

Secondary

MeasureTime frame
LKSS score;TCM symptom scale score;Knee joint ultrasonography;

Countries

China

Contacts

Public ContactWang Peng

Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

wangpeng@bjzhongyi.com+86 186 0002 1450

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026